• 1
    Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359362.
  • 2
    Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362364.
  • 3
    WHO. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997; 72: 341344.
  • 4
    Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 14631466.
  • 5
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825832.
  • 6
    Lunel F, Musset L. Hepatitis C virus infection and cryoglobulinemia. J Hepatol 1998; 29: 848855.
  • 7
    Ferri C, Caracciolo F, Zignego AL, La Civita L, Monti M, Longombardo G, et al. Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Haematol 1994; 88: 392394.
  • 8
    De Rosa G, Gobbo ML, De Renzo A, Notaro R, Garofalo S, Grimaldi M, et al. High prevalence of hepatitis C virus infection in patients with B-cell lymphoproliferative disorders in Italy. Am J Hematol 1997; 55: 7782.
  • 9
    Montella M, Crispo A, de Bellis G, Izzo F, Frigeri F, Ronga D, et al. HCV and cancer: a case-control study in a high-endemic area. Liver 2001; 21: 335341.
  • 10
    Mizorogi F, Hiramoto J, Nozato A, Takekuma Y, Nagayama K, Tanaka T, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin's lymphoma. Intern Med 2000; 39: 112117.
  • 11
    Zuckerman E, Zuckerman T, Levine AM, Douer D, Gutekunst K, Mizokami M, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 1997; 127: 423428.
  • 12
    McColl MD, Singer IO, Tait RC, McNeil IR, Cumming RL, Hogg RB. The role of hepatitis C virus in the aetiology of non-Hodgkins lymphoma—a regional association? Leuk Lymphoma 1997; 26: 127130.
  • 13
    Hausfater P, Cacoub P, Sterkers Y, Thibault V, Amoura Z, Nguyen L, et al. Hepatitis C virus infection and lymphoproliferative diseases: prospective study on 1,576 patients in France. Am J Hematol 2001; 67: 168171.
  • 14
    Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell JM, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98: 34063412.
  • 15
    Zeier M, Hartschuh W, Wiesel M, Lehnert T, Ritz E. Malignancy after renal transplantation. Am J Kidney Dis 2002; 39: E5.
  • 16
    Bjornadal L, Lofstrom B, Yin L, Lundberg IE, Ekbom A. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 2002; 31: 6671.
  • 17
    Ferri C, La Civita L, Zignego AL, Pasero G. Viruses and cancers: possible role of hepatitis C virus. Eur J Clin Invest 1997; 27: 711718.
  • 18
    Weng WK, Levy S. Hepatitis C virus (HCV) and lymphomagenesis. Leuk Lymphoma 2003; 44: 11131120.
  • 19
    Brincker H, Pedersen NT, Bendix-Hansen K, Johansen P. Non-Hodgkin's lymphoma subtypes over time in an unselected population of 646 patients: a study of clinico-pathological data and incidence based on a review using the REAL-classification. Leuk Lymphoma 2000; 39: 531541.
  • 20
    Centre for Epidemiology. National Board of Health and Welfare. Cancer Incidence in Sweden 2000. Official statistics of Sweden. Health and diseases 2002:5. Available at: Accessed September 1, 2004.
  • 21
    Weiland O, Berg JV, Bjorvatn B, Flehmig B, Lundbergh P. Acute viral hepatitis A, B and non-A, non-B in Stockholm in the 1950s and 1970s: a comparison. Infection 1981; 9: 268274.
  • 22
    Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology 2003; 125: 17231732.
  • 23
    Lunde AS, Lundeborg S, Lettenstrom GS, Thygesen L, Huebner J. The person-number systems of Sweden, Norway, Denmark, and Israel. Vital Health Stat 1980; 2: 159.
  • 24
    Mattsson B. Cancer registration in Sweden: studies on completeness and validity of incidence and mortality registers [dissertation]. Stockholm, Sweden: Karolinska Institutet, 1984.
  • 25
    Nilsson AC, Spetz CL, Carsjö K, Nightingale R, Smedby A. The reliability of the Hospital Discharge Register: the discharge diagnoses are more correct than the common belief [in Swedish]. Läkartidningen 1994; 91: 598605.
  • 26
    Blackberg J, Braconier JH, Widell A, Kidd-Ljunggren K. Long-term outcome of acute hepatitis B and C in an outbreak of hepatitis in 1969-72. Eur J Clin Microbiol Infect Dis 2000; 19: 2126.
  • 27
    Mansson AS, Moestrup T, Nordenfelt E, Widell A. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scand J Infect Dis 2000; 32: 253258.
  • 28
    Widell A, Hansson BG, Berntorp E, Moestrup T, Johansson HP, Hansson H, et al. Antibody to a hepatitis C virus related protein among patients at high risk for hepatitis B. Scand J Infect Dis 1991; 23: 1924.
  • 29
    Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T- lymphotropic viruses. Am J Public Health 1996; 86: 655661.
  • 30
    Boisvert J, He XS, Cheung R, Keeffe EB, Wright T, Greenberg HB. Quantitative analysis of hepatitis C virus in peripheral blood and liver: replication detected only in liver. J Infect Dis 2001; 184: 827835.
  • 31
    Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 8994.
  • 32
    Silvestri F, Barillari G, Fanin R, Pipan C, Falasca E, Salmaso F, et al. The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin's lymphoma. Leukemia 1997; 11: 21572161.
  • 33
    Westin J, Lindh M, Lagging LM, Norkrans G, Wejstal R. Chronic hepatitis C in Sweden: genotype distribution over time in different epidemiological settings. Scand J Infect Dis 1999; 31: 355358.
  • 34
    EkdahlK, ed. Communicable diseases in Sweden 2002. The annual report of the Department of Epidemiology. Stockholm: Swedish Institute for Infectious Disease Control, 2003.
  • 35
    Pradier C, Carrieri MP, Piche M, Rosenthal E, Dellamonica P, Serraino D. Hepatitis C virus infection and cancer risk among HIV-infected individuals. Infection 2003; 31: 194196.
  • 36
    Engels EA, Frisch M, Lubin JH, Gail MH, Biggar RJ, Goedert JJ. Prevalence of hepatitis C virus infection and risk for hepatocellular carcinoma and non-Hodgkin lymphoma in AIDS. J Acquir Immune Defic Syndr 2002; 31: 536541.
  • 37
    Hezode C, Duvoux C, Germanidis G, Roudot-Thoraval F, Vincens AL, Gaulard P, et al. Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation. HEPATOLOGY 1999; 30: 775778.
  • 38
    Shev S, Hermodsson S, Lindholm A, Malm E, Widell A, Norkrans G. Risk factor exposure among hepatitis C virus RNA positive Swedish blood donors—the role of parenteral and sexual transmission. Scand J Infect Dis 1995; 27: 99104.